Literature DB >> 6606740

Adverse effects on the brain in cardiac operations as assessed by biochemical, psychometric, and radiologic methods.

T Aberg, G Ronquist, H Tydén, S Brunnkvist, J Hultman, K Bergström, A Lilja.   

Abstract

In order to describe subclinical brain injury in conjunction with cardiac operations 94 patients were prospectively studied with three brain injury assessment methods: CSF analyses 24 hours after bypass, psychometry, and computed tomography of the brain. Adenylate kinase (AK), a marker of ischemic brain cell injury, was measured in cerebrospinal fluid (CSF) and in serum. In 13% of the patients, a considerable increase in CSF-AK was seen, in 46% there was a moderate increase, and in 41% no or trivial increase. Psychometry measured as change between preoperative scores in a test battery (SS3) revealed a moderate decrease in intellectual function after operation. There was a significant inverse correlation between CSF-AK and SS3 (r = -0.46, p less than 0.001, r2 = 0.21, n = 71). Computed tomography (CT) of the brain was performed preoperatively and postoperatively in 54 patients. Two of these had cerebral infarctions visible on the CT, despite an essentially normal postoperative state. There was no correlation between indices of brain injury and patient diagnosis and length of perfusion. It is concluded that subclinical brain injury is often seen after cardiac operations. Most often the injury appears trivial and/or reversible, but in a minority of cases there is evidence that the brain injury is irreversible. Factor analysis favors the view that the microembolism theory might no longer be a valid concept in modern cardiopulmonary bypass (CPB). Instead, circumstances in the operative field seem more likely to be important causative factors. This interpretation calls for new principles in the search for an improved cerebral protection during cardiac operations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6606740

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  11 in total

1.  Ketamine concentrations during cardiopulmonary bypass.

Authors:  R F McLean; A J Baker; S E Walker; C D Mazer; B I Wong; E M Harrington
Journal:  Can J Anaesth       Date:  1996-06       Impact factor: 5.063

2.  Cabbages and CABG.

Authors:  C M Allen
Journal:  BMJ       Date:  1988-12-10

Review 3.  Brain protection: physiological and pharmacological considerations. Part II: The pharmacology of brain protection.

Authors:  R Hall; J Murdoch
Journal:  Can J Anaesth       Date:  1990-10       Impact factor: 5.063

4.  A new device for evacuating air from the cardiac chambers.

Authors:  B T Zhong
Journal:  Tex Heart Inst J       Date:  1993

Review 5.  Brain protection: physiological and pharmacological considerations. Part I: The physiology of brain injury.

Authors:  J Murdoch; R Hall
Journal:  Can J Anaesth       Date:  1990-09       Impact factor: 5.063

Review 6.  Neurological and psychiatric adverse effects of anaesthetics: epidemiology and treatment.

Authors:  J M Klafta; J P Zacny; C J Young
Journal:  Drug Saf       Date:  1995-11       Impact factor: 5.606

7.  The impact of electroencephalography, pressure, and pO2 monitoring on the risk of stroke during cardiopulmonary bypass.

Authors:  J E Okies; U S Page; J C Bigelow; A H Krause; N W Salomon; K L Laxer
Journal:  Tex Heart Inst J       Date:  1986-03

8.  Early neurological complications of coronary artery bypass surgery.

Authors:  P J Shaw; D Bates; N E Cartlidge; D Heaviside; D G Julian; D A Shaw
Journal:  Br Med J (Clin Res Ed)       Date:  1985-11-16

9.  MRI: a method to detect minor brain damage following coronary bypass surgery?

Authors:  A Vik; A O Brubakk; P A Rinck; E Sande; O W Levang; O Sellevold
Journal:  Neuroradiology       Date:  1991       Impact factor: 2.804

Review 10.  Cognitive function after open-heart surgery: are postoperative neuropsychological deficits caused by cardiopulmonary bypass?

Authors:  R H Benedict
Journal:  Neuropsychol Rev       Date:  1994-09       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.